Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03960957 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines
A Phase 3 study of Glabellar Frown Lines, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 301
- Enrollment target
- 11
- Study locations
NCT03960957 is a Phase 3 study of Glabellar Frown Lines that has completed, run by Galderma R&D. The registered enrollment target is 301 participants. The trial reports 11 study locations across 9 states.
The verdict
NCT03960957, a Phase 3 study of Glabellar Frown Lines, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 301 participants
- Enrollment target
- 11
- Study locations
Study Summary
An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL AbobotulinumtoxinA
Study Locations (11)
California
- Galderma Study Site - Redondo Beach
- Galderma Study Site - San Diego
Texas
- Galderma Study Site - Austin
- Galderma Study Site - Spring
Connecticut
- Galderma Study Site - Westport
District of Columbia
- Galderma Study Site - Washington D.C.
Florida
- Galderma Study Site - Coral Gables
Georgia
- Galderma Study Site - Atlanta
Missouri
- Galderma Study Site - St Louis
Nebraska
- Galderma Study Site - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2019-06-17 |
| Est. Completion | 2020-04-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03960957
The ClinicalTrials.gov registry entry for NCT03960957 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 301 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glabellar Frown Lines appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03960957 reports 11 study locations spanning 9 distinct geographic areas - top geographies include California, Texas, Connecticut.
Frequently Asked Questions
What is clinical trial NCT03960957 about?
NCT03960957 is a clinical study titled "Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines". An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines
What is the current status of trial NCT03960957?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 301 participants. The study started on 2019-06-17. Estimated completion is 2020-04-16.
What conditions does trial NCT03960957 study?
This clinical trial studies the following conditions: Glabellar Frown Lines.
What interventions are being tested in trial NCT03960957?
The interventions under investigation include: Placebo (OTHER), AbobotulinumtoxinA (BIOLOGICAL).
Who is sponsoring clinical trial NCT03960957?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03960957 being conducted?
This trial has 11 study locations across California, Connecticut, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glabellar Frown Lines
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.